Sometimes in biotech, it's not about having a drug ready for market—it's about having the right tools to find the next big thing. That's the story behind Tenaya Therapeutics (TNYA)'s big move on Thursday, with shares soaring after the company announced a research collaboration with Alnylam Pharmaceuticals (ALNY) that could be worth up to $1.13 billion.

Let's break down what's actually happening here. Tenaya isn't selling a product or licensing a specific drug. Instead, they're bringing their specialized research capabilities to the table. The collaboration focuses on discovering human genetic targets for potential cardiovascular disease treatments—basically, finding the biological switches that, if turned on or off, might help treat heart conditions.

Tenaya will validate up to 15 gene targets and receive up to $10 million in upfront payments. The real potential comes from milestone payments that could reach that eye-popping $1.13 billion figure. For a company with a market cap that was under $100 million before this announcement, that's the kind of number that gets investors' attention.

The Tools in Tenaya's Toolbox

So what exactly is Tenaya bringing to this partnership? The company uses human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high throughput to identify genetic targets. In plain English: they take human stem cells, turn them into heart cells, and then run lots of experiments to figure out which genes matter for heart disease.

They also use human-engineered heart tissue and preclinical models of human disease to validate and characterize potential product candidates. Think of it as building miniature human hearts in the lab to test ideas before moving to human trials.

This isn't just theoretical science. Tenaya's target identification and validation capabilities have already generated more than 150 genetic targets and contributed to the discovery and development of their clinical-stage candidates, including the TN-201 and TN-401 gene therapies and TN-301 small molecule, plus several early-stage programs.

In December 2025, Tenaya shared interim data from the ongoing RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy for rare inherited heart disease. The data included safety, biopsy, and arrhythmia results from three patients who received TN-401 at a dose of 3E13 vg/kg.

Alnylam's Big Picture

This deal fits into Alnylam's broader strategy. In January, the company announced a new five-year roadmap called "Alnylam 2030" that outlines their focus on scaling operations. At the core is a push to establish durable global leadership in transthyretin (TTR) diseases—a group of conditions caused by abnormal protein buildup.

Alnylam aims to lead the TTR market in revenue by 2030 and cumulatively over the next five years. Partnering with Tenaya on cardiovascular targets represents an expansion into adjacent therapeutic areas while leveraging Alnylam's expertise in RNA interference technology.

The Market's Mixed Signals

Here's where things get interesting. Despite today's 31.20% surge to 76 cents per share, Tenaya is trading 29.1% below its 100-day simple moving average and 23.6% below its 200-day simple moving average. That indicates a bearish trend over the medium to long term.

The stock's Relative Strength Index stands at 40.21, suggesting it's neither overbought nor oversold—basically, there's room to move in either direction. The MACD indicator shows bearish momentum, with the MACD line below the signal line.

Analysts seem to like the story, even if they've been adjusting their expectations. The stock carries a Buy rating consensus, but recent moves show some caution:

• Canaccord Genuity maintained a Buy rating but lowered their target to $5 as of December 18, 2025
• HC Wainwright & Co. kept their Buy rating but lowered their target to $3 as of December 12, 2025
• Chardan Capital maintained a Buy rating but lowered their target to $8 as of December 12, 2025

What you're seeing here is the classic biotech dynamic: big potential future payoffs versus current financial reality. The Alnylam deal validates Tenaya's technology platform and provides near-term cash, but those billion-dollar milestones are years away—if they happen at all. For now, investors are betting that this partnership is the first step toward turning scientific capability into commercial success.